Login to Your Account

Agenus Is Hit Hard by GSK Trial Failure

By Catherine Shaffer
Staff Writer

Thursday, September 5, 2013
Shares of Agenus Inc., of Lexington, Mass., plummeted 23.5 percent on news that Glaxosmithkline plc’s Phase III DERMA trial testing its MAGE-A3 cancer immunotherapeutic, formulated with Agenus’s QS-21 Stimulon adjuvant, missed its primary endpoint.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription